

This notice in TED website: <https://ted.europa.eu/udl?uri=TED:NOTICE:46662-2020:TEXT:EN:HTML>

**United Kingdom-Bristol: Pathology services
2020/S 021-046662**

Voluntary ex ante transparency notice

Services

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority/entity

I.1) Name and addresses

Official name: North Bristol NHS Trust
Postal address: Southmead Road, Bristol
Town: Bristol
NUTS code: UKK11
Postal code: BS10 5NB
Country: United Kingdom
Contact person: Martin Strawson
E-mail: [martin.strawson@UHBristol.nhs.uk](mailto:martin.strawson@UHBrristol.nhs.uk)
Telephone: +44 1173420815

Internet address(es):

Main address: <https://www.nbt.nhs.uk/>

I.4) Type of the contracting authority

Other type: NHS trust

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title:

Procurement of a Large Throughput DNA Sequencer
Reference number: BWPCCL001501

II.1.2) Main CPV code

85111800

II.1.3) Type of contract

Services

II.1.4) Short description:

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per run, providing flexibility across a broad range of applications and study sizes. The NovaSeq

6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

II.1.6) **Information about lots**

This contract is divided into lots: no

II.1.7) **Total value of the procurement (excluding VAT)**

Value excluding VAT: 779 625.00 GBP

II.2) **Description**

II.2.1) **Title:**

II.2.2) **Additional CPV code(s)**

85111000

II.2.3) **Place of performance**

NUTS code: UKK11

II.2.4) **Description of the procurement:**

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier.

North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd.

NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity.

Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel.

This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

II.2.5) **Award criteria**

Quality criterion - Name: Quality / Weighting: 90

Price - Weighting: 10

II.2.11) **Information about options**

Options: no

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

Section IV: Procedure

IV.1) **Description**

IV.1.1) **Type of procedure**

Award of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below

- The procurement falls outside the scope of application of the directive

Explanation:

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier.

North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd.

NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

IV.1.3) **Information about framework agreement**

IV.1.8) **Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: no

IV.2) **Administrative information**

IV.2.1) **Previous publication concerning this procedure**

Section V: Award of contract/concession

Title:

Procurement of Large High Throughput DNA Sequencer

V.2) **Award of contract/concession**

V.2.1) **Date of contract award decision:**

28/01/2020

V.2.2) **Information about tenders**

The contract has been awarded to a group of economic operators: no

V.2.3) **Name and address of the contractor/concessionaire**

Official name: Illumina Cambridge Ltd
Postal address: Chesterford Research Park, Little Chesterford
Town: Saffron Walden
NUTS code: UKI
Postal code: CB10 1XL
Country: United Kingdom
The contractor/concessionaire will be an SME: yes

V.2.4) **Information on value of the contract/lot/concession (excluding VAT)**

Total value of the contract/lot/concession: 779 625.00 GBP

V.2.5) **Information about subcontracting**

Section VI: Complementary information

VI.3) **Additional information:**

VI.4) **Procedures for review**

VI.4.1) **Review body**

Official name: Bristol and Weston Purchasing Consortium
Postal address: Level 3, Whitefriars, Lewins Mead
Town: Bristol
Postal code: BS1 2NT
Country: United Kingdom
E-mail: martin.strawson@UHBristol.nhs.uk

VI.4.2) **Body responsible for mediation procedures**

Official name: Bristol and Weston Purchasing Consortium
Postal address: Level 3, Whitefriars, Lewins Mead
Town: Bristol
Postal code: BS1 2NT
Country: United Kingdom

VI.4.3) **Review procedure**

VI.4.4) **Service from which information about the review procedure may be obtained**

Official name: Bristol and Weston Purchasing Consortium
Postal address: Level 3, Whitefriars, Lewins Mead
Town: Bristol
Postal code: BS1 2NT
Country: United Kingdom

VI.5) **Date of dispatch of this notice:**

28/01/2020